Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 2 for:    light therapy | Interventional Studies | Perinatal Depression | United States

Personalized Integrated Chronotherapy for Perinatal Depression

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04364646
Recruitment Status : Recruiting
First Posted : April 28, 2020
Last Update Posted : October 19, 2020
Sponsor:
Collaborators:
Northwell Health
Johns Hopkins University
University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
Katherine M. Sharkey, Rhode Island Hospital

Brief Summary:
Perinatal depression and anxiety are common, serious, and frequently overlapping disorders that increase morbidity and mortality in new mothers (including suicide) and result in poor infant/child outcomes. Current therapies often fail to produce recovery or are poorly tolerated, and many pregnant women seek non-pharmacologic therapy or forgo treatment when non-pharmacologic options are not available. Expectant and new mothers who experience circadian rhythm dysregulation are at increased risk for perinatal depression. This Confirmatory Efficacy Clinical Trial of Non-Pharmacological Interventions for Mental Disorders R01 seeks to test whether a Personalized Integrated Chronotherapy (PIC) intervention can improve treatment outcomes for pregnant patients seeking outpatient treatment for depression, with or without anxiety. PIC is a multicomponent treatment consisting of bright light therapy, sleep phase advance, and sleep stabilization/restriction that targets the Research Domain Criteria (RDoC) constructs of circadian rhythms and sleep-wake behavior. To increase sample size and diversity and accelerate recruitment, this study will be performed at 4 sites that differ in clinical structure and that have piloted the PIC intervention. The study will enroll expectant mothers diagnosed with major depressive disorder during 3rd trimester of pregnancy. Participants will be randomized to either: (a) usual care (UC, n = 110) or (b) PIC+UC (n = 110). PIC+UC will have pregnancy and postpartum components and will be administered via a personalized approach tailored to optimize the intervention based on each patient's individual circadian and sleep timing. After a baseline assessment, PIC will be prescribed during 5 dedicated clinical visits: three during 3rd trimester of pregnancy and 2 in the postpartum period. UC will consist of medication and/or psychotherapy. UC will be quantified in both groups to evaluate differences between the PIC+UC and UC groups. Mood will be measured in both groups by blinded clinician interview and patient self-report. The safety profile of the PIC intervention will be assessed by evaluation of side effects/adverse events. Importantly, the study will also examine the target mechanisms by which PIC is hypothesized to work and test the mediation effects of the circadian targets on improvement in mood symptoms. Participants will wear wrist actigraphy/light monitors continuously during weeks 28-40 of pregnancy and postpartum weeks 2-6 to assess light exposure and to estimate sleep timing and duration. Circadian phase (measured with salivary dim light melatonin onset) will be measured at baseline during pregnancy (~30 weeks' gestation), at 36 weeks' gestation, and at postpartum week 6. Exploratory aims will examine associations between infant sleep behavior and maternal circadian rhythms and factors relevant to future dissemination of PIC. If this intervention is effective, perinatal PIC could change clinical practice and have major public health impact due to the high prevalence of perinatal depression and anxiety, the negative effects of mood disorders on mothers and their children, and the need to provide effective, novel, non-pharmacologic therapies for women with perinatal mood disorders.

Condition or disease Intervention/treatment Phase
Depression Postpartum Depression Prenatal Disorder Circadian Dysregulation Pregnancy Related Sleep Disturbance Behavioral: Personalized Integrated Chronotherapy Not Applicable

Detailed Description:

The purpose of this research study is to collect data on whether adding light therapy and a prescribed sleep schedule to usual treatment for depression can reduce depression and anxiety symptoms during pregnancy and the postpartum. The study is enrolling pregnant woman between the ages of 18 and 40 who have been diagnosed with depression and (possibly) anxiety.

This study takes place from the 3rd trimester of pregnancy to 18 weeks postpartum. Women who take part in this study will be randomly assigned ("randomized") into one of the study treatment groups (1) the "usual care" group (UC); or (2) the group that receives bright light therapy and a prescribed sleep schedule, also called the "Personalized Integrated Chronotherapy" group (PIC). The usual care group will receive medications and/or talk therapy as decided by the woman and her doctor. Women in the integrated chronotherapy group will receive usual care (as above) and will also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor. Light will be delivered with a portable, broad-spectrum light box. Both groups will have their sleep and light levels monitored during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and 18 after the baby is born (postpartum weeks 2-6 and 18) Sleep monitoring takes place in the home using a small wrist activity monitor called an "actigraph." Participants will also be asked to provide three saliva sample sets over the course of the study to measure melatonin levels.

In addition to the "Personalized Integrated Chronotherapy" study treatment that will supplement the clinical care as described above, participants will be asked to come in for research study visits.

Layout table for study information
Study Type : Interventional
Estimated Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Masking Description: outcome assessments are made by a blinded investigator
Primary Purpose: Treatment
Official Title: Personalized Integrated Chronotherapy for Perinatal Depression
Actual Study Start Date : October 1, 2020
Estimated Primary Completion Date : May 31, 2023
Estimated Study Completion Date : November 30, 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Usual Care
Women in the usual care group receive medications and/or talk therapy. Sleep and light levels are monitored at home with wrist actigraphy during 3rd trimester of pregnancy (weeks 28-40) and weeks 2-6 and18 after the baby is born (postpartum weeks 2-6 and 18).
Behavioral: Personalized Integrated Chronotherapy
Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
Other Names:
  • Chronotherapy
  • Triple Chronotherapy
  • Bright Light Therapy

Experimental: Personalize Integrated Chronotherapy
Women in the integrated chronotherapy group receive usual care (medications and/or talk therapy, as above) and also receive a bright light box to sit with every morning for up to 60 minutes as prescribed by the study doctor.
Behavioral: Personalized Integrated Chronotherapy
Based on their baseline sleep-wake schedule and real-life constraints (work and other responsibilities), an initial sleep schedule is set that allows 7.5 hours of sleep and provides time for participants to sit in front of the morning bright light.
Other Names:
  • Chronotherapy
  • Triple Chronotherapy
  • Bright Light Therapy




Primary Outcome Measures :
  1. Change in Depressive Symptoms [ Time Frame: change from baseline at 33 weeks of gestation ]
    Score on the Hamilton Depression Rating Scale (range=0-54, higher scores indicate more depressive symptoms)

  2. Change in Depressive Symptoms [ Time Frame: change from baseline at 36 weeks of gestation ]
    Score on the Hamilton Depression Rating Scale (range=0-54, higher scores indicate more depressive symptoms)

  3. Change in Depressive Symptoms [ Time Frame: change from baseline at 2 weeks postpartum ]
    Score on the Hamilton Depression Rating Scale (range=0-54, higher scores indicate more depressive symptoms)

  4. Change in Depressive Symptoms [ Time Frame: change from baseline at 6 weeks postpartum ]
    Score on the Hamilton Depression Rating Scale (range=0-54, higher scores indicate more depressive symptoms)

  5. Change in Depressive Symptoms [ Time Frame: change from baseline at 18 weeks postpartum ]
    Score on the Hamilton Depression Rating Scale (range=0-54, higher scores indicate more depressive symptoms)


Secondary Outcome Measures :
  1. Change in Circadian Phase [ Time Frame: change from baseline at 36 weeks pregnancy ]
    Time of salivary dim light melatonin onset (DLMO)

  2. Change in Circadian Phase [ Time Frame: change from baseline at 6 weeks postpartum ]
    Time of salivary dim light melatonin onset (DLMO)

  3. Change in Sleep Timing [ Time Frame: change from baseline at 33 weeks of pregnancy ]
    time of sleep onset and sleep offset measured with wrist actigraphy

  4. Change in Sleep Timing [ Time Frame: change from baseline at 36 weeks of pregnancy ]
    time of sleep onset and sleep offset measured with wrist actigraphy

  5. Change in Sleep Timing [ Time Frame: change from baseline at 2 weeks postpartum ]
    time of sleep onset and sleep offset measured with wrist actigraphy

  6. Change in Sleep Timing [ Time Frame: change from baseline at 6 weeks postpartum ]
    time of sleep onset and sleep offset measured with wrist actigraphy

  7. Change in Sleep Timing [ Time Frame: change from baseline at 18 weeks postpartum ]
    time of sleep onset and sleep offset measured with wrist actigraphy

  8. Infant sleep behavior [ Time Frame: 18 weeks postpartum ]
    infant sleep-wake patterns will be measured with one week of ankle actigraphy

  9. Melatonin levels and timing of onset in breastmilk [ Time Frame: 18 weeks postpartum ]
    We will examine associations between salivary melatonin levels and melatonin levels in breast milk



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Gender Based Eligibility:   Yes
Gender Eligibility Description:   people who can become pregnant are eligible, i.e., female sex; any gender identity can be enrolled but must be pregnant
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

- pregnant women, ages 18-40 years with a HAMD score >=14 and a current DSM-5 diagnosis of major depressive disorder as determined with the Current Major Depression Module of the Structured Clinical Interview for DSM disorders (SCID-I/P)

Exclusion Criteria:

  • active psychosis or suicidality contraindicating outpatient treatment as determined by the clinical judgement of the research team and as measured with the B/C module of the SCID-I/P and the Columbia-Suicide Severity Rating Scale
  • bipolar disorder (because sleep restriction can increase risk of conversion to mania)
  • seizure disorder (because sleep restriction can increase seizure risk)
  • self report of frequent migraines/headaches precipitated by bright light or sleep deprivation
  • preexisting eye/skin disorders contraindicating light therapy
  • use of photosensitizing medications
  • primary Axis I diagnosis other than MDD (e.g., anorexia nervosa, ADHD)
  • high risk pregnancy (e.g., conditions requiring mandatory bed rest or complex medical regimens that will interfere with study participation or conditions where poor infant outcomes are anticipated)
  • starting antidepressants in the 4 weeks prior to enrollment
  • current employment as night shift worker
  • Alcohol Use Disorders Identification Test (AUDIT) score > 8 and/or Drug Abuse Screening Test (DAST) > 1 indicating current alcohol or drug use disorders
  • women whose infants will not be living in the home or who will have a nighttime caregiver
  • Pittsburgh Sleep Quality Inventory (PSQI)190 < 5 (i.e., those who report no sleep complaints during 3rd trimester of pregnancy and for whom an intervention targeting sleep might not be indicated).
  • women who do not speak and read English because PIC research instruments are only available in English at this time. If this RCT shows effectiveness, future work will examine effectiveness in women who speak and read languages other than English.
  • Women who experience fetal loss or stillbirth, as well as mothers whose infants are born before 36 weeks' gestation or have NICU stays > 5 days, will be discontinued from the study but will continue to receive UC.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04364646


Contacts
Layout table for location contacts
Contact: Katherine M Sharkey, MD, PhD 401-421-9440 katherine_sharkey@brown.edu

Locations
Layout table for location information
United States, New York
Feinstein Institute For Medical Research Recruiting
Glen Oaks, New York, United States, 11004
United States, North Carolina
University of North Carolina Recruiting
Chapel Hill, North Carolina, United States, 27599
Contact: Samantha Meltzer-Brody, MD,MPH         
United States, Rhode Island
Rhode Island Hospital Recruiting
Providence, Rhode Island, United States, 02903
Contact: Katherine M Sharkey, MD, PhD         
Sponsors and Collaborators
Rhode Island Hospital
Northwell Health
Johns Hopkins University
University of North Carolina, Chapel Hill
Investigators
Layout table for investigator information
Principal Investigator: Kristina M Deligiannidis, MD Northwell Health
Principal Investigator: Jennifer Payne, MD Johns Hopkins University
Principal Investigator: Samantha Meltzer-Brody, MD University of North Carolina, Chapel Hill
Layout table for additonal information
Responsible Party: Katherine M. Sharkey, Principal Investigator, Rhode Island Hospital
ClinicalTrials.gov Identifier: NCT04364646    
Other Study ID Numbers: 18-0913
First Posted: April 28, 2020    Key Record Dates
Last Update Posted: October 19, 2020
Last Verified: October 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Per NIMH guidelines
Supporting Materials: Study Protocol
Clinical Study Report (CSR)
Time Frame: when study is concluded and data are prepared
Access Criteria: with approval from PI and regulatory bodies

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Depression, Postpartum
Depression
Depressive Disorder
Dyssomnias
Parasomnias
Chronobiology Disorders
Behavioral Symptoms
Mood Disorders
Mental Disorders
Sleep Wake Disorders
Nervous System Diseases
Puerperal Disorders
Pregnancy Complications